Assessing the impact of a symptom-based mass screening and testing intervention during a novel infectious disease outbreak: The case of COVID-19

Authors

Yang Ge[1], Department of Epidemiology and Biostatistics, The University of Georgia, Athens, GA, USA, https://orcid.org/0000-0001-5100-0703

Brian Kenneth McKay, Department of Epidemiology and Biostatistics, The University of Georgia, Athens, GA, USA, https://orcid.org/0000-0003-3859-7634

Shengzhi Sun, Department of Environmental Health, Boston University School of Public Health, Boston, MA, USA.

Feng Zhang, Department of Biostatistics and Data Science, University of Texas Health Science Center at Houston, School of Public Health, Houston, TX, USA.

Andreas Handel[2], Department of Epidemiology and Biostatistics, The University of Georgia, Athens, GA, USA, http://orcid.org/0000-0002-4622-1146

Corresponding author: $yang.ge@uga.edu^1$, $ahandel@uga.edu^2$

Abstract

A symptom-based mass screening and testing intervention (MSTI) can identify a large fraction

of infected individuals during an infectious disease outbreak. China is currently using this

strategy for the COVID-19 outbreak. However, MSTI might lead to increased transmission if not

properly implemented. We investigate under which conditions MSTI is beneficial.

Main Text

Rapid detection and isolation of infected individuals at the start of an outbreak is an important

part of containing infectious disease outbreaks [1,2]. A symptom-based mass screening and

testing intervention (MSTI), is an approach that can identify a significant fraction of infected

individuals. In the current novel coronavirus (COVID-19) outbreak, China is using an MSTI

strategy in an attempt to identify as many cases as possible [3]. While the concept of identify,

isolate, and treat is not new in terms of controlling an outbreak [4] the scales at which it is

currently being used is. A problem for a situation such as the COVID-19 outbreak is that many

novel pathogens show symptoms that are similar to common infections, e.g., general respiratory

symptoms. Since general respiratory symptoms are common, a MSTI can quickly overload the

health system [5]. Strained health facilities mean reduced care for individuals with other health

needs. In addition, such a situation might directly lead to a worsening of the outbreak, due to

increased transmission at testing sites [6,7]. We explore how the latter risk affects the potential

benefit of MSTI.

We consider a scenario where a novel pathogen has entered a population and causes symptoms

that are non-specific and similar to circulating pathogens, e.g., general respiratory symptoms.

The default is to ask individuals with symptoms to stay home and follow general precautionary

measures [8]. An alternative option is to implement MSTI, which requires testing anyone with

symptoms specific for the novel pathogen at a healthcare facility.

At any given time during an outbreak, a proportion, P, of those showing symptoms will be

infected with the novel pathogen. For symptomatic patients who stay home, the expected number

of transmissions of the novel pathogen caused by that person is the average number of

transmissions caused by someone who is infected with that pathogen (reproductive number, R),

multiplied by the probability the person is infected with the new pathogen, $T_H = RP$. Similarly,

such a patient has a mortality risk due to the novel pathogen of $M_H = MP$, where M is the

probability of death if a person enters a healthcare facility under regular circumstances, i.e.,

when they feel bad enough to seek medical care.

For individuals who go through an MSTI, there are two possible scenarios. If the symptomatic

individual is infected with the novel pathogen (probability P), we assume that they are correctly

identified and placed under isolation and treatment, where they have reduced transmission and

mortality risks, namely $R_I P$ and $M_I P$. Importantly, if the health system is strained, those patients

arriving at the testing facility without being infected with the novel pathogen (probability $1 - P$)

may become infected by another person in the testing facility. We denote this probability of

becoming infected with F. Since these individuals test negative, we assume they will be sent

home and then have the same transmission and mortality risk as individuals asked to remain at

home. Thus, the total transmission potential for a person undergoing screening is $T_S = R_I P +$

$RF(1 - P)$ and the total mortality risk is $M_S = M_I P + MF(1 - P)$.

We can define transmission and mortality risk ratios (TRR and MRR), which are given by

$TRR = T_S/T_H = R_I/R + (1 - P)F/P$ and $MRR = M_S/M_H = M_I/M_0 + (1 - P)F/P$. If that

expression is less than 1, it suggests that MSTI reduces transmission and mortality. If it is larger

than 1, the better strategy would be to not implement MSTI.

As a best-case scenario, we consider a situation where isolation and treatment following a

positive test are perfect, with $R_I = M_I = 0$ (other scenarios are explored in the SM). In that case,

TRR and MRR are the same and given by $(1 - P)F/P$. To keep this ratio below 1, the risk of

MSTI associated infection needs to be $F < P/(1 - P)$.

Figure 1 shows a heatmap for TRR or MRR (on a log scale) for different values of F and P. The

solid line is given by $F = P/(1 - P)$, at which TRR/MRR=1 (thus their log is 0). This line

marks the threshold at which MSTI changes from being beneficial to not being beneficial.

For small P, this is essentially a linear relationship, $F \approx P$. This means that if the fraction of

those infected with the novel pathogen among those with symptoms is low, MSTI is only

suitable if the risk of infection associated with MSTI is less than the fraction of syptomatic who

carry the novel pathogen. P will be low if the overall pathogen prevalence is low (e.g. early in an

outbreak) and if symptoms are so broad that only a small fraction of those individuals with

symptoms are infected with the novel pathogen. As P increases, a larger MSTI associated

infection risk is acceptable. Once P reaches a value of ≥ 0.5, MSTI becomes useful even if $F =$

1, i.e. MSTI associated infection is certain. If such a high P is reached because the novel

pathogen is widespread, MSTI is likely logistically unfeasible. If instead a high P can be reached

by better discrimination of symptoms, MSTI can be a useful strategy.

Figure 1: Transmission and mortality risk ratio (log scale) as function of novel pathogen prevalence among individuals showing symptoms, P, and testing-site related infection risk factor, F. For TRR/MRR the threshold at which MSTI becomes beneficial is 1, thus for the log shown here this threshold is 0. Everything below this threshold indicates that MSTI is helpful, above 0 it is not. Indicated in color are estimates for P and F ranges for 3 different pathogens (see SM for details).

While hard numbers for the quantities *F* and *P* for specific pathogens or outbreaks are

impossible to obtain, we used previously published data to obtain very rough estimates for *F* and

P ranges for the COVID-19 outbreak, as well as the 2014 Ebola outbreak and a combination of

previous measles outbreaks (see SM for details). Those estimates are shown as colored areas in

the figure. For both measles and COVID-19, our estimates suggest that depending on the specific

setting (e.g. a specific country), MSTI might or might not be beneficial. It seems more clearly

beneficial for Ebola, mainly due to Ebola-related symptoms that make the disease easier to

discriminate from other pathogens, thus leading to a higher P.

For MSTI to be beneficial, one needs to minimize F and maximize P [9]. An approach to reduce

F could be the use of dedicated testing sites separate from the usual healthcare facilities [10].

Staff at those sites can be trained to follow protocols that reduce transmission risk. One could

also ask symptomatic individuals to call a phone number and schedule a test, instead of allowing

individuals to self-report at any time. With a scheduling system, crowding can be reduced, and

when individuals show up at the scheduled time, they can be processed rapidly, thus reducing

transmission risk [6].

P can be increased by having a more specific case definition (ideally without losing sensitivity).

This would reduce the overall pool of individuals with symptoms and increases P among those

targeted for testing. More refined case definitions, screening by experts using telemedicine

approaches [11], or rapid home tests [12] could all be options which reduce the pool of those

considered at risk of being infected with the novel pathogen, thus increasing P. This will also

reduce the total number of individuals going to testing sites, likely reducing F.

Overall, our analysis suggests that MSTI can be useful if the probability of transmission at

testing sites is less than the probability that a symptomatic person is infected with the novel

pathogen. Both F and P will likely vary between settings and thus should be evaluated for a

specific setting, e.g. a specific country, if MSTI is considered as a potential control strategy.

References

1. Fraser C, Riley S, Anderson RM, Ferguson NM. Factors that make an infectious disease outbreak controllable. Proceedings of the National Academy of Sciences **2004**; 101:6146–6151.

2. Peak CM, Childs LM, Grad YH, Buckee CO. Comparing nonpharmaceutical interventions for containing emerging epidemics. Proceedings of the National Academy of Sciences **2017**; 114:4023–4028.

3. National Health Commission. Transcript of the press conference on February 4, 2020-National Health Commission of the People's Republic of China. 2020. Available at: http://www.nhc.gov.cn/wjw/xwdt/202002/35990d56cfcb43f4a70d7f9703b113c0.shtml. Accessed 5 February 2020.

4. Day T, Park A, Madras N, Gumel A, Wu J. When is quarantine a useful control strategy for emerging infectious diseases? American Journal of Epidemiology **2006**; 163:479–485.

5. Lipsitch M, Hayden FG, Cowling BJ, Leung GM. How to maintain surveillance for novel influenza a h1n1 when there are too many cases to count. The Lancet **2009**; 374:1209–1211.

6. Beggs CB, Shepherd SJ, Kerr KG. Potential for airborne transmission of infection in the waiting areas of healthcare premises: Stochastic analysis using a monte carlo model. BMC infectious diseases **2010**; 10:247.

7. Chowell G, Abdirizak F, Lee S, et al. Transmission characteristics of mers and sars in the healthcare setting: A comparative study. BMC medicine **2015**; 13:210.

8. Jefferson T, Foxlee R, Del Mar C, et al. Interventions for the interruption or reduction of the spread of respiratory viruses. Cochrane database of systematic reviews **2007**;

9. Kucharski AJ, Camacho A, Checchi F, et al. Evaluation of the benefits and risks of introducing ebola community care centers, sierra leone. Emerging Infectious Diseases **2015**; 21:393–399.

10. Hick JL, Hanfling D, Burstein JL, et al. Health care facility and community strategies for patient care surge capacity. Annals of emergency medicine **2004**; 44:253–261.

11. Parmar P, Mackie D, Varghese S, Cooper C. Use of telemedicine technologies in the management of infectious diseases: A review. Clinical Infectious Diseases **2015**; 60:1084–1094.

12. Mahase E. Coronavirus: Home testing pilot launched in london to cut hospital visits and ambulance use. BMJ **2020**; 368. Available at: https://www.bmj.com/content/368/bmj.m621.